Multivalent Nanomedicine to Treat High-Risk Pediatric Solid Tumors |
Children’s Hospital of Philadelphia / Garrett Brodeur, MD |
Reach Grants |
2019 |
Pennsylvania |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
LSD1 Inhibition to Treat T-cell Acute Lymphoblastic Leukemia/Lymphoma |
University of Virginia, School of Medicine / Michael Engel, MD/PhD |
Reach Grants |
2016 |
Virginia |
Targeting Chondroitin Sulphate Proteoglycan 4 (CSPG4) in Glioblastoma |
University of North Carolina / Gianpietro Dotti, MD & Barbara Savoldo, MD/PhD |
Reach Grants |
2017 |
North Carolina |
Targeted Inhibition of the DNA Damage Response Pathway: A Novel Intervention in the Treatment of Pediatric Leukemias |
National Cancer Institute / Andre Nussenzweig, Ph.D. |
Reach Grants |
2014 |
Maryland |
Identification of Rhabdomyosarcoma Therapies Using an Efficient Mouse and Drosophila Repurposing Screen |
Memorial Sloan-Kettering Cancer Center / Mary Baylies, Ph.D. |
Reach Grants |
2014 |
New York |
Identifying a Therapeutic Partner for TAK228 for Pediatric Phase II Brain Tumor Studies |
The Johns Hopkins University School of Medicine / Eric H. Raabe, MD/PhD |
Reach Grants |
2018 |
Maryland |
Immunotherapy for Pediatric Atypical Teratoid/Rhabdoid Tumor |
Baylor College of Medicine / William Decker, PhD |
Reach Grants |
2013 |
Texas |
B-lapachone as a Novel Targeted Therapy for ATRTs and other Pediatric Cancers
|
University of Texas Southwestern Medical Center / James Amatruda, MD, PhD |
Reach Grants |
2013 |
Texas |